‘Tis the Season for last-minute holiday shopping, and this year the rush is on. According to the National Retail Federation, more than 40 percent of people have shopping left to complete. Fortunately, shoppers can look to Wahl for those must-have, much-appreciated gifts for everyone on the list. The company’s “look good at the last minute” holiday lineup includes new, budget-friendly offerings in men’s grooming, massage therapy and pet. Plus, a new online destination, Wahlholidaygifts.com, makes looking good at the last minute easier than ever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55488-wahl-holiday-gifts-lineup-for-last-minute-shopping-wahlholidaygifts
By reprogramming a 7–year–old girl’s own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom–designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child’s doctors found that she had no evidence of cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/50777-chop-engineered-immune-t-cell-therapy-anticancer-effect-in-children
Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine today, with the goal to unlock genetic codes and develop drug therapies in real time to improve the outcome for thousands of young patients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59399-phoenix-children-s-hospital-visionary-institute-of-molecular-medicine
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, is simplifying the design, fitting and care of full-face masks for sleep apnea patients. With its unique modular design, the new Amara full-face mask further demonstrates Philips’ commitment to developing solutions aimed at improving care and outcomes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57117-philips-respironics-revolutionary-full-face-mask-sleep-therapy
http://www.trainorsportsmedicine.com
Trainor Sports Medicine is Dedicated To Safe Participation In Sports, we specialist in providing a concentration in pain control, for musculoskeletal injuries, which may include injections of cortisone, viscol supplementation including for example euflexxa, hyaline and synvisc as well as, prp (platelet rich plasma therapy).
http://www.trainorsportsmedicine.com
Trainor Sports Medicine - We provide a concentration in pain control, for musculoskeletal injuries, which may include injections of cortisone, viscol supplementation including for example euflexxa, hyaline, and synvisc as well as, prp (platelet rich plasma therapy).
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
On May 27, CVS/pharmacy launched a new in-store fundraising campaign named Advancing Medical Research, to support medical research and help improve the quality of life for those living with amyotrophic lateral sclerosis (ALS) and cystic fibrosis (CF). Funds raised through the campaign will benefit the ALS Therapy Alliance (ATA), a leading organization dedicated to advancing ALS research, and the Cystic Fibrosis Foundation, the world’s leader in the search for a cure for cystic fibrosis. Supporters for the 2012 campaign can donate $1 or $3 dollars at the register in CVS/pharmacy locations and online at www.cvs.com/alscff through June 30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56330-cvs-pharmacy-fundraising-campaign-support-als-and-cystic-fibrosis
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Superstar model, producer, television host and designer, Heidi Klum is known for her cutting-edge style and trademark tresses. Now Unilever is tapping the sophisticated fashion icon to help launch new CLEAR SCALP & HAIR BEAUTY THERAPY™, a revolutionary line of nourishing shampoos and conditioners that turns the conventional hair care discussion on its head. This new approach “feeds scalp,” not just the ends, and gives women stronger, more beautiful hair in just seven days.
“When it comes to women’s hair care, the emphasis has traditionally been on the ends, yet 99 percent of hair’s natural strength and beauty comes from the scalp. Scalp is skin and it is important to care for and nourish it just as we care for our skin. NEW CLEAR SCALP & HAIR BEAUTY THERAPY™ feeds the scalp and creates the right foundation for stronger, more beautiful hair in just seven days,” says David Rubin, U.S. Haircare Marketing Director for Unilever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55843-clear-scalp-and-hair-therapy
